ophiopogonin B: RN given refers to (1beta,3beta,25R)-isomer; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 46173857 |
| CHEBI ID | 80879 |
| MeSH ID | M0135894 |
| Synonym |
|---|
| unii-s18059b04u |
| s18059b04u , |
| beta-d-galactopyranoside, (1beta,3beta,25r)-3-hydroxyspirost-5-en-1-yl 6-deoxy-2-o-(6-deoxy-alpha-l-mannopyranosyl)- |
| ophiopogonin b |
| C17038 |
| 38971-41-4 |
| (-)-ophiopogonin b |
| .beta.-d-galactopyranoside, (1.beta.,3.beta.,25r)-3-hydroxyspirost-5-en-1-yl 6-deoxy-2-o-(6-deoxy-.alpha.-l-mannopyranosyl)- |
| prosapogenin d3 |
| CHEBI:80879 |
| AKOS032946028 |
| Q27151379 |
| HY-N1961 |
| FS-9827 |
| CS-0018279 |
| (2s,3r,4r,5r,6s)-2-[(2r,3r,4s,5r,6r)-4,5-dihydroxy-2-[(1s,2s,4s,5'r,6r,7s,8r,9s,12s,13r,14r,16r)-16-hydroxy-5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icos-18-ene-6,2'-oxane]-14-yl]oxy-6-methyloxan-3-yl]oxy-6-methyloxane-3,4,5-trio |
| EX-A8002T |
Ophiopogonin B (OP‑B) is a bioactive component of Radix Ophiopogson Japonicus. It is often used in Chinese traditional medicine to treat pulmonary disease.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Ophiopogonin B (OP‑B) is a bioactive component of Radix Ophiopogon Japonicus, which is often used in Chinese traditional medicine to treat pulmonary disease." | ( Ophiopogonin B suppresses the metastasis and angiogenesis of A549 cells in vitro and in vivo by inhibiting the EphA2/Akt signaling pathway. Chen, M; Fu, H; Guo, Y; Hu, C; Jiang, H; Jiang, R; Wu, M; Zhang, X; Zhou, Y, 2018) | 2.64 |
| "Ophiopogonin B (OP-B) is a bioactive component of Radix Ophiopogon Japonicus, which is often used in Chinese traditional medicine to treat pulmonary disease. " | ( Ophiopogonin B-induced autophagy in non-small cell lung cancer cells via inhibition of the PI3K/Akt signaling pathway. Chen, J; Chen, K; Chen, M; Du, Y; Duan, JΑ; Fu, HΑ; Huang, Z; Jiang, F; Jiang, M; Qui, M; Tang, Y; Wang, M; Xiong, F; Ye, L; Yin, L; Zhan, Z; Zhang, X; Zhou, J, 2013) | 3.28 |
| Class | Description |
|---|---|
| steroid saponin | Any saponin derived from a hydroxysteroid. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (11.11) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (66.67) | 24.3611 |
| 2020's | 2 (22.22) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.15) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 9 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||